2 No-Brainer Growth Stocks to Buy and Hold for Years
While some companies struggle with particularly turbulent macroeconomic conditions, others continue to exhibit resilience and enrich shareholders in the process. Investing in the latter companies can help your portfolio to ride out market storms and boost your returns over the long run.
Here are two stocks to consider adding to your portfolio right now.
Vertex Pharmaceuticals (NASDAQ: VRTX) remains the unequivocal leader in cystic fibrosis (CF) treatment, a space on track to be worth $32 billion by the year 2027. In 2020, 2021, and 2022, Vertex had profits of $2.7 billion, $2.3 billion, and $3.3 billion, respectively. Revenue totaled $9 billion in 2022, an 18% increase from the prior year.
Source Fool.com
